

COMMUNICATION OF OTHER RELEVANT INFORMATION

October 24th, 2023

Pursuant to the provisions of article 17 of Regulation (EU) No. 596/2014 on market abuse and in article 228 of the consolidated text of the Law of Stock Market, approved by Royal Legislative Decree 4/2015, of 23 October, and concordant provisions are made available to the market the following information regarding ATRYS HEALTH, S.A. (onwards, "ATRYYS"):

Main business figures for the third quarter 2023:

ATRYYS announces that it is beginning to publish the main figures of the evolution of business financial selected information related to first and third quarter of each fiscal year together with the publication of the Consolidated Financial Statements for the first half of the year under limited review and the Audited Consolidated and Individual Financial Reports for the year.

Attached to this OIR is the presentation of the evolution of business financial selected information related to the third quarter of fiscal year 2023.

Madrid, October 24th, 2023

Isabel Lozano Fernández

CEO

25th October 2023

3Q 2023 Key figures

Warning / Disclaimer and Cautionary Statements



This document may contain forward-looking statements and information (hereinafter "Statements") relating to ATRYS HEALTH, S.A., or the ATRYS Group (hereinafter "ATRYS", the "Company" or the "Group"). These statements may include financial projections and estimates with assumptions, statements regarding plans, objectives, and expectations that may relate to various matters, including, but not limited to, the customer base and its evolution, the growth of the various lines of business, market share, the company's results and other aspects relating to the company's activity and situation.

The forward-looking statements or forecasts contained in this document may be identified, in certain cases, by the use of words such as "expects", "anticipates", "intends", "believes" or similar language, or their corresponding negative form, or by the predictive nature of matters relating to strategies or plans or intentions. These forward-looking statements or forecasts reflect the views of ATRYS with respect to future events and are not, by their nature, guarantees of future performance and are subject to risks and uncertainties that could cause actual developments and results to differ materially from those expressed in these intentions, expectations or forecasts. Such risks and uncertainties include those identified in the documents with more complete information filed by ATRYS with the various supervisory bodies of the securities markets on which its shares are listed, and in particular with the Spanish Securities Market Commission (CNMV).












Except to the extent required by applicable law, ATRYS undertakes no obligation to publicly update the outcome of any revisions it may make to these statements to conform to events or circumstances after the date hereof, including, without limitation, changes in the Company's business, business development strategy or any other circumstances that may arise. This document may contain summary financial information, non-GAAP or unaudited information. The information contained herein should be read as a whole and is subject to all publicly available information about the Company, including, where applicable, other documents issued by the Company containing more complete information.

Finally, it is noted that neither this document nor anything contained herein constitutes an offer to buy, sell or exchange, or a solicitation of an offer to buy, sale or exchange of securities, or a recommendation or advice on any security.

Atrys, 360° Health Services



Atrys is a global provider of healthcare services. We bring a comprehensive healthcare service that offers innovative healthcare solutions customised for each patient to any part of the world.

BUSINESS AREAS	 atrys oncology	 atrys diagnostics	 atrys preventive care	Compliance
ACTIVITY	High-precision radiotherapy Medical Oncology (Chemo/Immuno)	Laboratories Pathology and Genetics Telemedicine Nuclear medicine	Healthcare services and health checkup for companies Primary Health Care Safety and prevention training services for companies	Data protection E-commerce compliance Fulfillment with legal and regulatory requirements
REVENUES SPLIT	 25%	 28%	 35%	 12%
CLIENTS	Healthcare Insurance companies and Hospital Groups	Healthcare Insurance companies and Hospital Groups	Companies	SMEs
GEOGRAPHICAL FOOTPRINT				

Guidance 2023




We maintain Guidance for the financial year 2023.

Without incorporating M&A transactions


Turnover evolution

EUR million



Adjusted EBITDA evolution

EUR million



Key figures for 3Q 2023



Continued strong performance of the key figures in 3Q 2023 with robust EBITDA growth supported by operating leverage due to business growth.

('000 EUR)

	NIIF UE		Chg (%) 2022/23	NIIF UE		Chg (%) 2022/23
	3Q 2022	3Q 2023		9M 2022	9M 2023	
Turnover	43.541	51.288	17,8%	134.347	169.524	26,2%
Gross Margin ^(APM)	32.662	34.894	6,8%	109.231	121.109	10,9%
<i>% Gross Margin</i>	<i>75,0%</i>	<i>68,0%</i>		<i>81,3%</i>	<i>71,4%</i>	
EBITDA ^(APM)	1.511	4.383	190,1%	17.038	27.200	59,6%
Non recurrent expenses	37	1.528	3997,8%	4.738	4.612	-2,7%
Adjusted EBITDA ^(APM)	1.548	5.911	281,8%	21.776	31.811	46,1%
<i>% Adjusted EBITDA</i>	<i>3,6%</i>	<i>11,5%</i>		<i>16,2%</i>	<i>18,8%</i>	
Total Capex ^(APM)	(4.179)	(1.376)	-67,1%	(8.529)	(8.354)	-2,0%
Capex	(1.771)	(850)	-52,0%	(3.193)	(2.563)	-19,7%
Growth Capex	(1.901)	0		(3.455)	(3.187)	-7,8%
Capex R&D	(507)	(525)	3,6%	(1.881)	(2.604)	38,5%
Operating Cash Flow ^(APM)	(2.668)	3.007	-212,7%	8.509	18.846	121,5%
Adj. Operating Cash Flow ^(APM)	(2.631)	4.536	-272,4%	13.248	23.457	77,1%
Adj operating Cash Flow - Growth Capex ^(APM)	(730)	4.536		16.702	26.644	59,5%

Unaudited figures

^(APM) See definitions of alternative performance measures in Annex I.

Revenue growth of **+26.2%** to **€169.5m** in the first nine months of FY2023 (+10.7% like for like and +11.6% ex COVID-related revenues). The third quarter of the year is the quarter with the seasonally lowest activity in the Preventive Medicine area.

Gross Margin growth of **+10.9%** to **€121.1m**. Reduction of the decrease in Gross Margin on revenues shown in the first half of 2022 from 11.1% to 9.9% in the first nine months of 2023.

EBITDA improved by **+59.6%** to **€27.2m**, due to containment of OPEX expenses.

Adjusted EBITDA improved by **+46.1%** to **€31.81m**.

In the first nine months of the 2023 financial year, **CAPEX** investment amounted to **€8.35m** (-2% compared to €9m in 2022), of which **€3.2m** corresponds to **expansion CAPEX** (opening of the Madrid laboratory, drug mixing centres in Mexico and Barcelona Nuclear Medicine centre).

Operating Cash Flow increased by **+121.5%** and **Operating Cash Flow adjusted for non-recurring expenses** increased by **77.1%** compared to the first nine months of FY2022.

Key figures for 3Q 2023



Like for like' turnover development on a like for like basis

Turnover by business segment

(^{'000 EUR})

	3T 2022	3T 2023	Var %	9M 2022	9M 2023	Var %
1) Precision Medicine	25.388	28.649	12,8%	76.972	88.653	15,2%
1.1) Oncology	12.690	14.115	11,2%	38.605	42.366	9,7%
2.2) Diagnostics	12.698	14.534	14,5%	38.367	46.287	20,6%
2) Preventive Medicine	15.752	15.816	0,4%	56.060	58.456	4,3%
3) Compliance services	4.866	6.823	40,2%	19.161	22.781	18,9%
Total Turnover ex COVID revenues	46.005	51.288	11,5%	152.193	169.890	11,6%
COVID revenues	29	0		1.300	0	
Total Turnover	46.034	51.288	11,4%	153.493	169.890	10,7%

Unaudited figures

(APM) See definitions of alternative performance measures in Annex II.

Proforma 2022 includes the full year impact of the acquisitions of Significant (Bienzobas), Chilerad, Chaxa and Initia.

Like-for-like revenue growth on a like-for-like basis¹ is +11.6% excluding COVID test revenues and **+10.7%** including 2022 COVID test revenues.

Growth in **Oncology** revenues of **+9.7% in the** first nine months of the year, driven by the growth of the Medical Oncology area and the positive performance of the radiotherapy area in Spain and Portugal.

Good performance of the **Diagnostics** area with **+20.6%** growth in the first 9 months of FY2023 driven by the strong demand for Telemedicine services in Spain and Chile and Nuclear Medicine in Spain and Portugal and the opening of the pathology laboratory in Madrid.

Growth of **+4.3%** in the area of **Preventive Medicine** due to an improvement in the client retention rate.

Strong growth in the **Compliance area** in Q3, driven by strong growth in compliance services for SMEs.

Track record

In the last 5 years ATRYS has established itself as a global consolidator by integrating 17 companies to lead precision medicine and prevention segments.


#1 Spanish-language B2B tele-diagnostic company, with a leading position in Spain, Chile and Colombia.

Market leader in private oncology treatments in Spain.

#3 player in preventive medicine in Spain by market share.

Well established platform in Nuclear Medicine diagnosis and treatment in Spain and Portugal.

More than 6 million diagnostics per year in 7 countries, integrating AI tools to optimize diagnostic processes.





Thank you!

Annex II

Alternative Average Performance Definitions ^(MAR)

GROSS MARGIN ^(MAR)

Gross Margin^(MAR) corresponds to net sales less supplies. Gross Margin is considered by the Group as a measure of the performance of its activity, as it provides information on net sales, subtracting the cost incurred to achieve these sales.

GROSS MARGIN OVER TURNOVER
^(MAR)

The **Gross Margin**^(MAR) corresponds to the Gross Margin ^(GM) divided by turnover.

EBITDA ^(MAR)

EBITDA^(MAR) corresponds to the sum of "Gross income", "Group work on assets", "Other operating income", "Allocation of grants for non-financial fixed assets and others" and "Operating expenses", subtracting from other operating expenses customer provisions corresponding to income generated in previous years and other provisions that do not involve a cash outflow.

Adjusted EBITDA ^(MAR)

Adjusted EBITDA as a percentage of
turnover ^(MAR)

Adjusted EBITDA per share ^(MAR)

Adjusted EBITDA^(MAR) corresponds to EBITDA^(MAR) for the year excluding **non-recurring expenses**^(MAR). One-shot non-recurring expenses are those arising from capital market transactions and from M&A activity, severance payments for redundancies in jobs that are amortised, or the impact on operating results arising from employee incentive plans that can be remunerated with Group shares, as well as extraordinary provisions of a non-recurring nature and any other operating and optimisation adjustments that involve an initial and one-off expense that is offset over the following 12 months.

CAPEX ^(MAR)

CAPEX R&D ^(MAR)

CAPEX Growth ^(MAR)



As well as the amount of incentive plans for the Group's management team recognised in an expense account that do not result in a cash outflow.

In addition, it will count as recurring EBITDA for the year the synergies detected in 12 months under a specific Cost Savings Plan.

Adjusted EBITDA^(MAR) on revenue ^(MAR) corresponds to adjusted EBITDA ^(MAR) for the year divided by revenue.

Adjusted EBITDA per share^(MAR) : Corresponds to EBITDA ^(MAR) divided by the total number of shares issued.

CAPEX^(MAR) corresponds to cash outflows incurred in relation to the productive capacity and profitability of the Group's assets and is reflected in the Consolidated Financial Statements in the statement of cash flows from investing activities, excluding business acquisitions (Business Unit). CAPEX is defined as funds used by the Group to purchase, improve, maintain or develop its tangible or intangible assets, such as buildings, machinery, technology or equipment.

CAPEX R&D ^(MAR) corresponds to the investment in assets related to the development of the Group's R&D activity. It is the sum of additions to Development and additions to Industrial Property in the Group's Intangible Fixed Assets.

CAPEX R&D ^(MAR) corresponds to CAPEX investment linked to projects that will generate future income from new activities.

Annex II



Alternative Average Performance Definitions ^(MAR)

OPERATING CASH FLOW ^(MAR)

Operating cash flow ^(MAR) means EBITDA ^(MAR) for the period minus CAPEX ^(MAR) and CAPEX R&D ^(MAR) .

ADJUSTED OPERATING CASH FLOW ^(MAR)

Adjusted operating cash flow ^(MAR) means adjusted EBITDA ^(MAR) for the period minus CAPEX ^(MAR) and CAPEX R&D ^(MAR) .

GROSS FINANCIAL DEBT ^(MAR)

GROSS FINANCIAL DEBT ^(GFD) Gross financial debt is the sum of the following items: "Amounts owed to financial institutions", "Amounts owed to public entities", "MARF Bond Programme", "Convertible Bonds" and loans related to acquisitions to be repaid out of cash. Convertible Bonds" and loans related to acquisitions to be repaid out of cash.

NET FINANCIAL DEBT ^(MAR)

WORKING CAPITAL ^(MAR)

NET FINANCIAL DEBT ^(FCF) means gross financial debt less cash and cash equivalents, guarantees and deposits and deposits that qualify as immediate liquid assets or are intrinsically linked as collateral for one of the gross debt items.

Working Capital ^(WC) is the result of subtracting current assets from current liabilities. Working capital or working capital is a financial aggregate used to measure the performance of the group's activity and provides an analysis of liquidity, operating efficiency and short-term financial health.